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Abstract MicroRNAs are short endogenous RNA mole-
cules that are able to regulate (mainly inhibiting) gene
expression at the post-transcriptional level. The MicroRNA
expression profile is cell-specific, but it is sensitive to
perturbations produced by stresses and diseases. Endothe-
lial cells subjected to metabolic stresses, such as calorie
restriction, nutrients excess (glucose, cholesterol, lipids)
and hypoxia may alter their functionality. This is predictive
for the development of pathologies like atherosclerosis,
diabetes, and hypertension. Moreover, cancer cells can
activate a resting endothelium by secreting pro-angiogenic
factors, in order to promote neoangiogenesis, which is
essential for tumor growth. Endothelial altered phenotype
is mirrored by altered mRNA, microRNA, and protein
expression, with a microRNA being able to control path-
ways by regulating the expression of multiple mRNAs. In
this review we will consider the involvement of microR-
NAs in modulating the response of endothelial cells to
metabolic stresses and their role in promoting or halting
angiogenesis.
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Abbreviations
ECs Endothelial cells
VEGF Vascular endothelial growth factor
bFGF Basic fibroblast growth factor
ROS Reactive oxygen species
NO Nitric oxide
eNOS Endothelial nitric oxide synthase
TFs Transcription factors
MicroRNAs
MicroRNAs are a class of endogenous 22–25 nt non-cod-
ing single-stranded RNA molecules that regulate gene
expression post-transcriptionally. MicroRNAs can affect
multiple cell processes, like proliferation, apoptosis, dif-
ferentiation, and also development [1].
MicroRNAs are transcribed by RNA polymerase II as
longer molecules (pri-miRNAs). The ribonuclease Drosha
maturates them into hairpin structure (pre-miRNAs), then
exported into the cytoplasm, where another ribonuclease,
Dicer, cuts the loop, forming a double-stranded RNA mol-
ecule. One of the two strands is degraded, whereas the other,
the mature microRNA, is incorporated into RISC (RNA-
induced silencing complex), which mediates its action [2].
MicroRNAs generally bind to the 30 UTR of target genes
and inhibit their translation [3], but in other instances they
have also been shown to destabilize the targeted mRNA [4].
Each microRNA can potentially bind several (hundreds)
target messenger RNAs through a very short (down to six
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nucleotides) complementary region, called ‘‘seed’’, which
perfectly pairs with the mRNA 30 UTR sequence.
The most challenging issue about microRNA study is
the recognition mechanism and so the identification of
mRNA targets. Informatic algorithms (TargetScans, Pic-
Tar, Miranda, to name a few) help to find probable targets,
but the binding needs always experimental validation for
each candidate target. Besides, since these algorithms are
based on different criteria, they give different output tar-
gets and each of them has a high probability to produce
either false-positive or -negative results.
So far, several experimental approaches for the identi-
fications of microRNA targets have been developed [5].
They are based on transcriptome analysis [4], protein
analysis [6], or biochemical approaches [7, 8].
The cell dynamics, arising from the connectivity of
genes and proteins, is extremely complex, and unpredict-
able, although deterministic. As a consequence of the
imperfect base-pairing mechanism, the same miRNA, in
different contexts, is able to drive the cell towards different
phenotypes. For that, miRNAs are natural candidates to a
central role in cellular adaptability mechanisms.
When deciphering a phenomenon like a metabolic stress
or tumor progression, microRNA expression profiling often
reveals, as for mRNA expression profiling, tens of
microRNAs differently expressed. Indeed, microRNA
expression has been found so distinguishing in pathological
states that microRNA profiling has been suggested as a
biomarker to classify human cancers [9]. Moreover,
Gallagher et al. [10] analyzed microRNAs and mRNAs of
skeletal muscle insulin-resistant patients and used a rank-
ing system to identify pathways affected by the disease.
The regulation of gene expression by microRNAs is fine
and complex at the same time. Each miRNA potentially
interacts with several mRNAs so that miRNA (interfer-
ence) network and gene expression network are embedded
to each other [11].
Both microRNAs and TFs are metazoan gene regulators,
sharing common features like pleiotropy, combinatorial
and cooperative mechanism of action. MicroRNAs and TFs
are also involved in coregulational network motifs (Fig. 1).
MicroRNA depletion, for example miR-221 and miR-
222 depletion, besides changing mRNA expression,
induced changes in microRNA expression, with nine mi-
croRNAs up-regulated and 23 microRNAs down-regulated
[12]. This finding envisages a model in which a microRNA
can affect the expression of transcription factors (TFs) or
components of the microRNA processing machinery, so
that the overall microRNAs are in turn affected.
This issue was further developed by means of compu-
tational models to assess the extent of regulation of gene
expression mediated by combinations of TFs and
microRNAs [13], inferring that genes are more likely to be
co-regulated by pairs of TFs or pairs of miRNAs than by
pairs of TF-miRNA, perhaps due to a higher probability of
evolutionary duplication events of shorter DNA sequences.
Chen et al. [14] analyzed the biological processes enri-
ched for different regulation types and they found that two
biological processes (pigmentation and reproduction)
require a coordinate TFs-microRNA coregulation. On the
other hand, it turned out that biological adhesion, devel-
opmental and cellular processes are enriched in
microRNA–microRNA coregulation types, suggesting that
microRNAs should carefully coordinate to regulate these
processes.
The computational model by Tsang et al. [15] revealed
the existence of two classes of circuits, respectively, neg-
ative and positive transcriptional coregulation of a miRNA
and its targets. These circuits can lead to a feedback and
feedforward loop of regulation. One main example is
represented by the MYC-miR-17-92 cluster-E2F1 circuit,
in which MYC induces expression of both E2F1 and the
miR-17-92 cluster, the latter in turn represses E2F1
expression (Fig. 2) [16]. This ‘‘genetic buffering’’ seems
intended to minimize noise in the level of E2F1 protein. A
similar kind of circuit can be seen for other microRNAs,
specifically for those with antithetic functions displayed in
different contexts. MiR-20a, belonging to miR-17-92
cluster, is part of the MYC-miR-17-92 cluster-E2F1self-
regulating and has a double role in tumorigenesis and
senescence, according to the endogenous level of E2F1
[17].
The bioinformatic research for microRNAs targeting
VEGF exemplifies the presence of regulatory modules. As
hypoxia induces VEGF, microRNAs down-regulated by
hypoxia were evaluated for their direct regulation of
VEGF, according to the presence of binding site in the
VEGF mRNA sequence. VEGF was regulated by multiple
microRNAs (miR-15b, miR-16, miR-20a, miR-20b) that
Fig. 1 Schematic representation of a network comprising TFs,
microRNAs, and target genes with the possible regulatory motifs
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displayed co-regulatory effects on other angiogenic factors
in CNE cells (nasopharyngeal carcinoma line) and also a
combinatorial mechanism of action [18]. This mechanism
envisages the possibility that microRNAs could compete
for a binding site (multimiRNA binding site) or they
cooperate by synergistically reinforcing the inhibition of
the same target, binding it in several points. This has been
shown, for example, for miR-15b, miR-24, miR-25, and
miR-141, whose joint reduction is necessary to increase
MKK4 abundance in replicative senescence [19]. More
recently, a cooperative microRNA network (comprising
miR-19b, miR-20a, miR-26a, miR-92, and miR-223) has
been claimed responsible to inhibit tumor suppressor genes
and promote T cell acute lymphoblastic leukemia [20].
Endothelial cells
Blood vascular endothelial cells (ECs) line the inner part of
the blood vessels and thus interface the blood with the rest
of the tissues. This position enables ECs to mediate several
functions. In concert with the immune cells, they play a
role in the inflammation process: by modulating the inter-
cellular junctions they can become more or less permeable
and therefore promote inflammation and edema, while the
surface molecules expressed on EC membrane permits
leukocytes (neutrophils) adhesion and migration. ECs
regulate the coagulation process by secreting von Wille-
brand factor; they also control blood flow and pressure by
mediating vasodilation or vasoconstriction through the
secretion of paracrine factors acting on smooth muscle
cells [21, 22].
ECs are normally quiescent, with a turnover of several
months [23], but they can be activated by pro-angiogenic
factors released by damaged tissues during physiological
processes like regeneration in wound healing or during the
menstrual cycle in the endometrium. Pro-angiogenic fac-
tors, like VEGF (vascular endothelial growth factor) and
bFGF (basic fibroblast growth factor), mediate the forma-
tion of new vessels from pre-existing ones, a phenomenon
called angiogenesis. ECs, activated in response to these
stimuli, divide and migrate to sprout new vessels. While
this phenomenon is to be promoted after an ischemic stress
in order to form collateral vessels that can again provide
nutrients and oxygen to the tissues, it should be counter-
acted in a tumor context. Cancer cells, in fact, secrete
growth factors to sustain blood supply for their nutriment
and also migration. Thus, the resulting imbalance between
pro-angiogenic and antiangiogenic stimuli (thrombospon-
din and endothelin, for instance) determines the phenotype
of an EC: if the balance tips towards pro-angiogenic fac-
tors, an angiogenic switch occurs.
ECs are directly subjected to physico-chemical stresses
(shear stress, hypoxia, glucose, cholesterol, lipids), which
are able to alter gene expression, interfere with cellular
metabolism, induce molecular modifications, and enhance
reactive oxygen species (ROS) production. The result is
that the response to pro- or antiangiogenic factors of ECs
are deeply modified. From a certain perspective, metabolic
stresses themselves could be seen as (mainly) antiangio-
genic stimuli when applied to ECs because they imbalance
the EC intracellular context and, as a consequence, they
modify EC response towards the extracellular environment.
The endothelial dysfunction is defined as the incapacity
of endothelium to maintain vascular homeostasis, mainly
due to the interference with the synthesis of NO (nitric
oxide), which is the principal vasodilating factor produced
by ECs [24]. This condition is linked to the development of
diseases as atherosclerosis [25], hypertension, diabetes, and
cardio vascular diseases [26]. This is translated into mod-
ified expression of endothelial markers and impaired
angiogenic properties that in vitro are measured as the
ability to migrate, proliferate, and form tube-like structures
in response to pro-angiogenic stimuli. In molecular terms,
these alterations in endothelial functionality are the results
of complex interactions between transcriptional and trans-
lational processes. Potential mediators of these processes
are microRNAs that modulate and are modulated by TFs,
thus functioning as regulatory molecules of gene expres-
sion networks.
Metabolism of endothelial cells
ECs line all the vases, from the capillaries to the venous
and arterial compartments. The venous or arterial fate of
ECs is regulated during vasculogenesis [21] and ECs
maintain their diversity in the adult gene expression pro-
files (reviewed in [27]). This accounts for the different
morphology and functions of the two compartments,
principally related to the O2 partial pressure and hemody-
namics. The arteries and arterioles are responsible for the
vascular tone and are subjected to shear stress; on the other
Fig. 2 Schematic representation of a network motif with a feedfor-
ward loop mediated by cMYC to E2F1 and a negative feedback
regulatory loop mediated by miR-17-92 cluster to E2F1
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hand, the veins are larger but with thinner walls, so that the
blood flows slower and is less oxygenated and more prone
to leukocyte trafficking [21, 28].
In the endothelium, ECs line according to the blood flow
and are resting cells [23, 29] adapted to survive in hypoxic
condition and in the presence of ROS [30]. This was further
supported by the finding that ECs stabilize the transcription
factor HIF1a (hypoxia-induced factor 1 a, a transcription
factor activated at low O2 levels that up-regulates genes
involved in glycolysis and angiogenesis) at a lower O2
concentration than other cells [31].
Peters et al. [29] compared the metabolic capacities of
freshly isolated HUVEC with in vitro cultivated ones (three
passages) and, according to others [30, 32], they found
‘‘aerobic glycolysis’’ in ECs. In fact, cell cultivation,
leading to increased proliferation, enhances glycolysis as
well as other pathways (tricarboxylic acid cycle, fatty
oxidization, pentose phosphate cycle) still active in ECs
but at a less extent compared to glycolysis. Thus, it appears
that mitochondria in ECs act as signaling organelles more
than source of ATP. Chronic, small increases in NO levels
stimulate mitochondrial biogenesis in diverse cell types
[33], conversely, higher levels of NO produced by ECs
inhibit cell respiration by binding to cytochrome c oxidase.
The inhibition of oxidative phosphorylation by NO
increases ROS production, which can function activating
AMPK (50 adenosine monophosphate protein kinase) [31];
in turn, O2 is diverted from the mitochondria towards the
cytosol where it activates prolyl hydroxylases (O2 sensing
enzymes that inactivate HIFs), therefore the cells do not
register hypoxia [34].
MicroRNAs involved in metabolic stresses
and disorders
Hypoxia
Hypoxia, which means diminished oxygen concentration,
can occur during ischemia, stroke, tumor growth, and at
high altitude. Oxygen-sensing enzymes, like prolyl
hydroxylases, promote HIF1a proteasomal degradation at
normal O2 concentration; conversely, when O2 concentra-
tion drops, HIF1a is free to enter the nucleus,
heterodimerize with HIF1b, and act as a transcription
factor. The pathways activated by HIF1a promote EC
proliferation, migration, and angiogenesis, but may also
mediate cell death, if the hypoxic stimulus has been too
severe [35].
Hypoxia mediates HIF1a-dependent up-regulation of
miR-210 both in primary ECs and in cancer cell lines [36–
38]. MiR-210 was found to stimulate tubulogenesis and
chemotaxis of ECs by inhibiting Ephrin A3 [38] and to
modulate mitochondrial function by decreasing iron-sulfur
cluster assembly proteins ISCU1/2 [37, 39] and COX10
[39] (Table 1), key factors of the mitochondrial electron
transport chain and tricarboxylic acid cycle. This has
important consequences: mitochondrial respiration activity
is inhibited, whereas ROS are generated. This environment
favors the metabolic switch from respiration to glycolysis
(the Warburg effect), which is typical of cancer cells
adapted to a hypoxic condition. Recently, miR-200b, which
directly target Ets-1, an important angiogenesis-related
transcription factor, has been shown to be downregulated
by hypoxia. Its downregulation promotes migration and
tube formation of ECs [40].
ROS, as superoxide and hydrogen peroxide, are
by-products of cellular metabolism being able to damage
lipids, proteins, and nucleic acids. Excessive or sustained
ROS production are implicated in atherosclerosis, hyper-
tension, diabetic cardiovascular complications, and
ischemia–reperfusion injury. Otherwise, an emerging body
of evidence has been showing that in moderate concen-
tration, ROS are able to regulate cellular functions. In
vascular ECs, the principal enzymes responsible for ROS
generation are NAD(P)H oxidase, xanthine oxidase,
uncoupled eNOS (endothelial nitric oxide synthase), and
mitochondrial electron leakage, while conditions like
hypoxia stimulate ROS production. The produced ROS
(above all mitochondrial ROS) are able to regulate vascular
tone, oxygen sensing, cell growth and proliferation, apop-
tosis, and inflammatory responses [41].
Hyperglycemia
Hyperglycemia is recognized as a major determinant
causing vascular problems in diabetes mellitus, obesity,
and metabolic syndrome that may be traced back to
endothelial dysfunction. The latter is strictly linked to
insulin resistance, because insulin is able to activate eNOS
[42, 43] and also because endothelial dysfunction and
insulin resistance share common factors triggering their
onset: glucotoxicity, lipotoxicity, and inflammation [44].
Four main molecular mechanisms have been implicated in
glucose-mediated vascular damage: (i) increased flux
through the polyol pathway; (ii) protein kinase C (PKC)
activation; (iii) increased hexosamine pathway activity;
(iv) increased production of advanced glycation end-
products (AGEs). In fact, the more glucose that enters the
cells and the tricarboxylic acid cycle, the more electron
donors (NADH and FADH2) are generated and therefore
electrons tend to block in the complex III of the mito-
chondrial electron transport chain and are donated to O2
one at a time, forming superoxide. ROS activate the
poly(ADP-ribose) polymerase (PARP), which in turn
inhibits the glycolytic enzyme glyceraldehyde-3 phosphate
F. Patella, G. Rainaldi
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dehydrogenase (GAPDH). This inhibition directly causes
activation of AGE and PKC pathways, while the accumu-
lation of upstream glycolytic metabolites, fructose-6
phosphate and glucose itself, causes the activation of the
hexosamine pathway and polyol pathway, respectively
[45]. Increased oxidative stress is the final outcome and
hence the leading feature that underlies endothelial dys-
function onset and progression [46, 47].
ECs cultured in high glucose to mimic hyperglycemic
conditions have a reduced proliferation rate and a
pronounced increase in apoptosis compared to cells grown
in normal glucose [48–50]. An inhibitory effect of high
glucose on migration and angiogenic potential [51–54], an
impairment of eNOS functionality and expression [42, 55–58]
and an increased expressionof the adhesionmolecules ICAM-
1, ELAM, VCAM [59–62] have also been reported.
ECs use mainly GLUT1 as a glucose transporter. At
normal glucose concentration, this transporter is not
up-regulated by insulin, but an insulin-stimulated GLUT1
up-regulation and consequent glucose uptake has been
Table 1 MicroRNAs regulating angiogenic properties in response to metabolic stresses
Stress MicroRNA Targeta MicroRNA functional
impact on angiogenic
properties
Cell type References
Hypoxia :miR-210 Ephrin A3 Promotion of migration and
tube-like structure formation
Human ECs (HUVEC) [38]
ISCU1/2 COX10 Inhibition of mitochondrial
respiration
Human ECs (HPAEC, HUVEC,
HAEC), colon cancer cell lines
[37, 39]
Hypoxia ;miR-200b Ets-1 Inhibition of migration and
tube-like structure formation
Human ECs (HMEC) [40]
Population doubling :miR-217 SIRT1 Promotion of senescence Human ECs (HUVEC) [103]
Inhibition of tube formation
Population doubling :miR-34 SIRT1 Promotion of senescence
Inhibition of proliferation
Human ECs (HUVEC) [105]
High glucose,
hyperglycemia
:miR-320 IGF-1 Inhibition of proliferation
and migration
GK rat ECs (MMVEC) [65]
CD71 Inhibition of proliferation Human leukemia cell line (HL-60) [66]
PIK3R2 (p85) Insulin resistance Mouse adipocytes (3T3-L1) [67]
HSP20 Apoptosis Rat cardiomyocytes [68]
High glucose :miR-221 c-kit Inhibition of proliferation
and migration
Human ECs (HUVEC) [75]
High glucose, AGEs ;miR-221 P27KIP1
P57KIP2
Promotion of proliferation Human ECs (HUVEC) [77]
CCND1 Inhibition of proliferation Human head and neck
carcinoma cell line
UMSCC10B
[80]
High glucose/low
growth factor
:miR-503 Cdc25 G1 phase cell cycle arrest Mouse C2C12 myoblast 81]
Cdc25, CCNE1 Inhibition of proliferation
and tube-like structure
formation
Human ECs (HUVEC) [79]
Low cellular sterol T miR-33 ABCA1
ABCG1
NPC1
Inhibition of
cholesterol efflux
Human ECs (Ea-hy), human and
mouse hepatocyte and monocyte
cell lines mouse hepatocyte and
monocyte cell lines human
hepatocyte and monocyte cell
lines
[91]
Ox-LDL :miR-125a-5p PreproET-1 Control vasoconstriction Murine cardiac microvascular
ECs (H5V)
murine brain microvascular
ECs (b.END.3)
[95]
;miR-125b
a Target validated by gene reporter assay
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reported at high glucose concentration [63]. ECs are not
able to regulate efficiently the transport of glucose to
maintain its intracellular concentration constant [64] and
hence, unlike other cell types, they suffer damage from
hyperglycemia.
The first microRNA reported being mis-expressed in
ECs exposed to hyperglycemia is miR-320. It was found to
be increased, among other microRNAs, in micro vascular
ECs (MMVEC) isolated from type 2 diabetes Goto Kaki-
zaki (GK) rats compared to control Wistar rats. Its
inhibition promoted proliferation and migration of GK
MMVEC, presumably by targeting IGF-1 [65]. Other direct
targets of miR-320 have been identified and validated: the
transferrin receptor CD71, with a role in cell proliferation
in a leukemia cell line [66]; PI3 K subunit p85 in insulin-
resistant adipocytes [67]; the heat shock protein HSP20 in
cardiomyocytes [68]. An inverse correlation (suggesting at
least an indirect regulation) was observed between the
expression of miR-320 and cyclin-dependent kinases 6
(CDK6) in primary murine bronchial epithelial cells [69],
and Mcl-1 in cholangiocytes [70]. On the whole, in these
cell lines miR-320 has an anti-proliferative role. This
finding was further supported by other works, where miR-
320 is listed in the down-regulated microRNAs in colon
cancer [71], breast cancer [72], cholangiocarcinoma [70],
cell lung carcinoma [73], and epigenetically regulated in
pancreatic cancer [74].
Li et al. [75] researched in high glucose-treated HUVEC
the EC specific miR-221, whose recognized target is c-kit
[76], and found it over-expressed, with a role in inhibiting
cell migration. Different results were obtained by Togliatto
et al. [77], who found miR-221 and miR-222 over-
expressed in ECs treated with high glucose or AGEs. They
demonstrated also in vivo that impaired vessel formation
mediated by high glucose andAGEs is controlled bymiR-221
and miR-222 by targeting the cell cycle regulators P27KIP1
and P57KIP2. MiR-320 and miR-221 were also found over-
expressed in type 2 GK rat livers (miR-221) [78], and in 3T3
adipocytes rendered insulin resistant through high glucose
and high insulin treatment (miR-320) [67], suggesting that
these microRNAs may have a broad involvement in glucose
homeostasis in insulin-targeted tissues. miR-221-222 have
also a role in tumor progression and in angiogenesis
(see later).
The expression of miR-503 was found increased in
myocardial ECs from type 2 GK rats [65], in 3T3-L1
insulin-resistant adipocytes [67] and also in muscle of type
2 diabetes and insulin-resistant human patients [10]. MiR-503
is up-regulated in HUVEC grown in high glucose/low
growth factors-containing medium (to mimic diabetes and
starving condition caused by ischemia); in limb muscle and
plasma of diabetic patients with critical limb ischemia
and in the ischemic muscle and ECs of diabetic mice [79].
MiR-503 down-regulates the expression of the cell cycle
regulators cyclin D1 (CCND1) [80], cdc25a [79, 81] and
cyclin E1 (CCNE1) [79]. In HUVEC, miR-503 forced
expression led to impaired migration, adhesion, network
formation capacities, and impaired proliferation due to an
increase of G0/G1-arrested cells. MiR-503 also reduced
vascular smooth muscle cells proliferation and migration,
which are instrumental for arteriogenesis. Conversely,
miR-503 inhibition restored normal proliferation and in
vitro angiogenesis of ECs grown in high glucose/low
growth factors-containing medium, without affecting EC
functions under normal culture conditions [79]. In diabetic
mice with induced limb ischemia, the inhibition of
miR-503 by injecting an adenoviral vector containing a
decoy sequence for miR-503 normalized post-ischemic
blood flow and muscular neovascularization, as well as
cdc25a and CCNE1 expression [79] (Table 1). These
findings suggest that miR-503 antagonizes post-ischemic
neovascularization in diabetes mellitus and thus it can be
considered a potential therapeutic target to improve healing
of diabetic ischemic tissues.
Hypertriglyceridemia and hypercholesterolemia
It is well known that chronic hypertriglyceridemia and
hypercholesterolemia are risk factors in the development of
atherosclerosis. It is widely accepted that hypertriglyceri-
demia leads to endothelial activation and dysfunction and it
is associated to superoxide anion production and decrease
in NO bioavailability [82, 83]. In fact, the release of free
fatty acids during triglyceride hydrolysis of chylomicrons
and VLDL (very low-density lipoprotein), mediated by EC
membrane lipoprotein lipase, may cause endothelial cell
injury and initiate thrombotic events [84, 85].
Superoxide anion in ECs is mainly produced by enzy-
matic oxidants: uncoupled eNOS (mainly due to decrease
in the cofactor tetrahydrobiopterin, BH4) and by NADPH
oxidase [26, 86, 87]. The mechanism of LDL oxidation is
not well clarified, but it seems to involve the endothelium
itself. ROS in the sub-endothelial space can oxidize free
fatty acids and low-density lipoprotein (ox-LDL). Also
phospholipase A2 and lipoxygenase are involved in LDL
lipoperoxidazion. Ox-LDL are highly immunogenic, attack
the arterial intima and activate ECs and monocytes,
increasing proinflammatory gene activity and uptake by
macrophages. This is the initial step in the formation of
fatty streaks that finally turn in the atheromatous plaque
[88]. ECs treated with ox-LDL in vitro show decreased
expression of eNOS [89], increased proliferation, and
hypertrophy [90].
Lipid and cholesterol metabolism is regulated mainly in
liver and adipose tissue. The most expressed microRNAs in
liver is miR-122, whose inhibition results in lowering
F. Patella, G. Rainaldi
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cholesterol plasma levels both in mammals and non-human
primates and also in the treatment of chronic hepatitis C
virus infection. MiR-33 is also involved in cholesterol
metabolism. This microRNA, besides being expressed in
hepatocytes and macrophages, is expressed in ECs (Ea-hy
cell line) [91] and it represses genes involved in cholesterol
mobilization: ABCA1 (in human and mouse cells),
ABCG1 (in mouse cells), NPC1 (in human cells). MiR-33
acts in a synergistic manner with its host gene SREBF2
[91, 92], a transcription factor which regulates the
expression of genes involved in cholesterol biosynthesis
and uptake. Moreover, SREBF2 in turn down-regulates
ABCA1 in vascular ECs (Fig. 3) [93]. In this view, miR-33
and SREBF2 regulate cholesterol homeostasis and reverse
cholesterol transport (the mechanism that regulates circu-
lating levels of HDL) in several tissues: under low cellular
sterol concentration miR-33 and SREBF2 are up-regulated
and inhibit cholesterol efflux through apolipoprotein A1 by
ABCA1 and through HDL by ABCG1; vice versa, when
the cellular cholesterol concentration is high, they are
down-regulated to allow the cholesterol import through the
membrane transporters. Mice transgenically deficient for
miR-33 [94] or inhibited for miR-33 expression by tail
injection of LNA miR-33 antisense [92] or by infection
with lentivirus coding for antimiR-33 [91] result in the
over-expression of ABCA1 and increased plasma HDL
levels. Thus miR-33 inhibition appears to be a valuable
strategy to rise HDL levels, but the cellular level of cho-
lesterol might be impaired.
There are not many studies about microRNA dysregu-
lated in the endothelium of animals fed with high-fat diets
or in ECs challenged with high cholesterol or high fat. A
recent work shows that miR-125a-5p is increased after 6 h
of ECs stimulation with ox-LDL, whereas miR-125b is
constitutively decreased. These microRNAs are both
decreased in aorta of stroke-prone spontaneously hyper-
tensive (SHR-SP) rats, where they are associated with up-
regulation of preproET-1 (the precursor of endothelin 1)
expression, which is their validated target [95] (Table 1).
Conversely, miR-125a-5p is up-regulated in ox-LDL-trea-
ted monocytes where it mediates lipid uptake and decreases
the secretion of some inflammatory cytokines (interleukin-
2, interleukin-6, tumor necrosis factor-a, transforming
growth factor-b) and ORP9 (oxysterol-binding protein-like
9) in monocyte-derived macrophages [96].
Calorie restriction
Calorie-restriction diets have been associated to increased
life span in yeast, mice, and also in non-human primates
[97]. The overall mechanism is not yet well understood, but
it has been hypothesized that caloric and metabolic
restriction causes lifespan extension by decreasing the
target of the rapamycin (TOR) pathway, which is the most
sensitive nutrient pathway in cells, which would lead to a
decrease in protein synthesis and a promotion of autophagy
[98]. It has also been found that calorie restriction induces
increase of eNOS expression, which is responsible for
mitochondrial biogenesis and in part for sirtuin 1 (SIRT1)
expression [99]. In fact, another consequence of calorie
restriction is the increased ratio [NAD?/NADH] that pro-
motes the activation of NAD?-dependent protein
deacetylase sirtuins [100], which are able to epigenetically
regulate gene expression and are associated with increased
lifespan. Moreover, SIRT1 was shown to prevent stress-
induced senescence in ECs [101] and control angiogenic
functions through the transcription factor FOXO1 and
eNOS [102].
It has been reported that miR-217 expression increases
in senescent human ECs in vitro (late passages HUVEC;
high population doubling) and in human atherosclerotic
plaques, promoting SIRT1 inhibition through a direct
binding [103]. Also, miR-34 (already known for its tumor-
suppressor actions) [104], was found to regulate senes-
cence in ECs by targeting SIRT1 [105] (Fig. 4).
Angiogenesis
The formation of new blood vessels from pre-existing ones
is called angiogenesis. The process is active in the embryo,
during the menstrual cycle, in the placenta, and during
wound healing [106, 107]. Angiogenesis plays a role in
adulthood pathologies, like autoimmune diseases, angio-
proliferative disease, degenerative and metabolic diseases
and cardiovascular diseases associated to tissue ischemia.
Moreover, a great number of neoplasia is able to induce the
formation of new vessels needed for the growth of the
tumor bulk and for its metastatic diffusion (cancer neoan-
giogenesis). From human to animal cancer models arises
the evidence that angiogenesis can be switched on at dif-
ferent stages of tumor progression, according to the cancer
Fig. 3 Schematic representation of a network comprising miR-217
and miR-34 and SIRT1 that promotes senescence of ECs
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type and its microenvironment. Human cancers arise in the
absence of angiogenic activity and can lie dormant for
months and years, before the rise of the angiogenic and
then malignant phenotype. The angiogenic switch activa-
tion has been ascribed to the synthesis and releases of pro-
angiogenic factors by the tumor itself [108–110]. The
balance hypothesis for the angiogenic switch [110] states
that the level of inhibitors and activators governs the pas-
sage from EC quiescence to angiogenesis. This balance is
altered through an increased expression of activators or a
reduced concentration of endogenous inhibitors.
ECs have a pivotal role in angiogenesis, thanks to the
interaction between the receptors on their membrane and
the pro-angiogenic factors. The triggered signal transduc-
tion pathways promote the proliferation, migration, and
morphologic organization of ECs in tight connection with
the surrounding environment. The formation of new ves-
sels goes through several well-defined stages characterized
by modifications of both the endothelium and the extra-
cellular matrix. In the first stage, there is the destabilization
of a pre-existing vessel with increase permeability and loss
of intercellular junctions. In the second stage, migration
and proliferation of ECs occur, helped by the release of
proteolytic enzymes to degrade the extracellular matrix,
thus favoring migration. Highly motile filopodia-extending
endothelial ‘‘tip cells’’ stay at the forefront of a vessel
sprout, guiding it towards the angiogenic stimulus. Behind
them there are the proliferating ‘‘stalk cells’’ that elongate
the vessel [111]. In the third stage, there is the differenti-
ation of ECs: they stop proliferating, form primitive
capillaries, and return quiescent. In this phase, the
recruitment of supporting peri-endothelial cells, namely
pericytes and smooth muscular cells, as well as the reor-
ganization of intercellular interactions, occur [112].
Several pro-angiogenic factors have been identified,
among which VEGF, TGFb (transforming growth factor
beta), IL-8 (interleukin 8), PDGF (platelet-derived growth
factor). Other factors have instead an inhibitory role, as
TSP-1, INFb (interferon beta). Also, proteases control the
availability of inhibitors or promoters: bFGF for instance
can be sequestered in the extracellular matrix and be
released after the matrix proteolytic degradation [113];
plasminogen, involved in the coagulation cascade, gives
rise to plasmin and also angiostatin, a potent angiogenesis
inhibitor [114]. Also, the signal of adhesion molecule is
important: quiescent vessels express a set of integrins,
whereas nascent capillaries express another set [115].
Tumor growth exceeding 1 mm3 demands glucose and
O2, which are insufficiently provided by the already-pres-
ent vasculature. Cancer cells secrete factors promoting
angiogenesis, but the new vessels are characterized by an
altered morphology and structure (functional shunting is
present [116]) and are composed by tumor ECs, loosely
attached pericytes and abnormal basement membrane.
The mRNA transcription profile characterizing the
angiogenic switch has been analyzed by comparing human
microvascular ECs treated with endostatin, a potent angi-
ogenesis inhibitor, or VEGF and/or bFGF, potent
angiogenesis activators [117]. Cluster analysis revealed
more than 2,000 inversely regulated genes, among which
‘‘hub’’ genes, nodal genes in the angiogenesis pathway,
were identified, namely PPARd(peroxisome proliferative
activated receptor d), STAT3, MMP1, c-FLIP, ROBO/
SLIT1.
A similar analysis has been made comparing the tran-
scription profiles of four types of dormant tumors (breast
carcinoma, glioblastoma, liposarcoma, and osteosarcoma)
to corresponding fast-growing tumors. The latter showed a
pronounced angiogenic phenotype, confirmed also at
transcriptional levels, while dormant tumor expressed a
high level of angiogenesis inhibitor, like TSP1 and also
novel markers of tumor dormancy were identified, like
Ephrin receptor A5 and H2BK [118].
MicroRNAs involved in inhibiting/promoting
angiogenesis
Dicer ablation
The initial works on microRNA function were designed as
loss-of-function experiments, where it was tried to decrease
all the microRNAs either in organisms or in cultured cells.
This was done by targeting Dicer and Drosha, the enzymes
devoted to microRNA synthesis and maturation.
Fig. 4 Schematic representation of cholesterol efflux. When intra-
cellular cholesterol is low, miR-33 and its host gene SREBF2 are up-
regulated and inhibit cholesterol efflux through ABCA1 (in human
and mouse cells) and ABCG1 (in mouse cells)
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The first evidence about an involvement of microRNAs
in mammalian angiogenesis came in 2005, when Yang
et al. [119] reported about mice severely hypomorphic for
the dicer allele (dicerex1/2), the terminal nuclease respon-
sible for the maturation of microRNAs. Mice died between
E12.5 and E14.5 and showed a primary vascular structure,
testifying that vasculogenesis was not affected, whereas
angiogenesis was totally impaired, despite high levels of
VEGF and its receptors [119]. Other Dicer hypomorphic
mice (generated by gene-trap) were viable, but female were
infertile, due to the impaired vessel formation in the ovary
and consequent corpus luteum insufficiency [120]. Dicer
silencing, performed in ECs in vitro using a siRNA,
impaired EC migration, proliferation and tube formation,
both in vitro and in vivo (Matrigel plug assay) [121, 122].
The gene expression pattern of Dicer-depleted cells is
somewhat surprising: several pro-angiogenic cytokines and
growth factor receptors were up-regulated, as well as
eNOS, Tie2, and AKT (but its phosphorylation was
inhibited) [121, 122]. Conversely, TSP1 expression was
up-regulated [122]. Drosha silencing induced minor phe-
notypic alterations and it was not effective in vivo [122]. It
is important to say that in these works, Dicer and Drosha
silencing brought to a small decrease in microRNAs (about
30%, with some microRNA more decreased than others)
and this could have rearranged the balance between
microRNAs and their targets. Moreover, the hypoxic
environment that was formed could have promoted the
expression of pro-angiogenic factors.
It is worth saying that Dicer-silenced HMEC, despite
having high levels of VEGF, produced less basal pro-
angiogenic ROS through NADPH oxidase when activated
with VEGF, phorbol ester (phorbol myristate acetate,
PMA) and TNFa, because of a reduction in the p47phox
NADPH oxidase subunity [123]. This was independent
from VEGF, suggesting that the Dicer-dependent miRNAs
regulate the angiogenic response downstream of VEGF.
Antiangiogenic microRNAs
Among the first microRNAs with a reported role in angi-
ogenesis were miR-221 and 222. They were shown to be
highly expressed in HUVEC [121, 122] and, according to
bioinformatic tools, they were predicted and then validated
with GFP reporter assay to target the c-kit receptor [76].
This receptor binds the SCF ligand to promote in vitro tube
formation, proliferation, and migration, which are then
inhibited by miR-221-222. This observation was also made
by Chen et al. [124] who reported another pathway regu-
lated by miR-221 in ECs. They showed that miR-221
promotes GAX expression by directly down-regulating the
repressor ZEB2. GAX expression, as miR-221, was high in
quiescent vascular cells and in serum-depleted cells. GAX
acted inhibiting EC proliferation by promoting p21 tran-
scription [125] and angiogenesis through inhibition of
NF-jB pathway [126]. Besides miR-221, miR-130a was
demonstrated to down-regulate GAX and HOXA5 (an
antiangiogenic homeobox gene) expression in ECs (Fig. 5)
[127]. In this case, miR-130a is up-regulated by serum and
pro-angiogenic factors and, once over-expressed in ECs,
counteracted the antiangiogenic activity of GAX and
HOXA5 that normally keep ECs in their resting state. MiR-
222 (but not miR-221) was also down-regulated after
pro-inflammatory stimuli (IL-3, bFGF) that promote
inflammation-mediated neoangiogenesis and intraplaque
vessel formation and it was found to directly target
STAT5A, a transcription factor known to be activated by
IL3 and bFGF signaling [128].
MiR-15a/16-1 cluster is composed by miR-15a and
miR-16 and it has been found lost in several lymphoid
malignancies, like chronic lymphocytic leukemia (CLL)
and multiple myeloma (MM), whereas a role as tumor
suppressor has been ascribed to this cluster. Gatt et al.
[129] reported about the knock down of the cluster for loss-
of-function studies by using a lentiviral system to stably
transduce MM cells with the miR-16 ‘‘sponge’’, a sequence
able to sequester and inhibit both miR-16 and its seed
family member miR-15a. The resulting MM cells were
more proliferating and, once injected in recipient mice,
could increase tumor load and angiogenesis. The analysis
of the gene expression profiling of cluster-depleted cells
helped to find out targeted genes, among which appeared
FGFR1, PI3KCa, MDM4, and VEGFa (Table 2). It is
noteworthy that miR-16 was demonstrated to pair to the
30UTR binding site and inhibit translation driven by the
VEGF IRES-B, but not IRES-A [130]. Cellular IRES
(internal ribosome entry sites) are normally found in genes
encoding critical growth regulatory genes, like VEGF.
Fig. 5 Schematic representation of opposite networks comprising
miRNAs and TFs. When miR-221 is high (in quiescent ECs), it
up-regulates the TF GAX by inhibiting the repressor ZEB2.
Consequently, p21 is up-regulated and cell proliferation is inhibited.
On the contrary, serum and pro-angiogenic factors increase miR-130
expression, leading to the down-regulation of its direct target, GAX,
so that cell proliferation and angiogenesis are favored
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VEGF is translated from two start codons, each of which is
regulated by an independent IRES, leading to the produc-
tion of different VEGF isoforms. The finding that
microRNAs are able to control gene expression also
through IRES is important because it adds another level of
microRNA regulation on protein expression.
MiR-92a, a component of miR-17-92 cluster, contrary to
the other members, conferred antiangiogenic properties to
HUVEC in vitro and in vivo (Matrigel plug assay) and its
over-expression induced defects in intersegmental vessel
formation in zebrafish [131]. MiR-92a expression was
increased in a hind-limb ischemia model and after induc-
tion of acute myocardial infarction in mice. Systemic
injection of antagomir-92a reduced necrosis and improved
perfusion and recovery of ischemic limb and enhanced
recovery after myocardial infarction. eNOS expression and
Table 2 MicroRNAs involved in angiogenesis driven by pro/antiangiogenic factors or tumor context
Pro/antiangiogenic
stimulus
microRNA Targeta MicroRNA
function
Cell type References
SCF ;miR-221 c-kit Inhibition of angiogenesis Human ECs (HUVEC) [76]
Quiescent, serum-depleted
cells
:miR-221 ZEB2 Inhibition of proliferation Human ECs (HUVEC) [124]
IL-3 bFGF ;miR-221 STAT5A Inhibition of angiogenesis Human ECs (HUVEC) [128]
Serum, VEGF, bFGF :miR-130a GAX Regulation of angiogenesis Human ECs (HUVEC) [127]
HOXA5
Cancer ;miR-15a-16 FGFR1 Inhibition of proliferation
and angiogenesis
Multiple myeloma cell line [129]
PI3KCa
MDM4
VEGFa
Hind-limb ischemia
model, acute
myocardial infarction
:miR-92 ITGA5 Inhibition of angiogenesis Human ECs (HUVEC) [131]
VEGF, bFGF cancer :miR-132 P120RasGAP Promotion of angiogenesis Human ECs (HUVEC),
human embryonic stem
cell vasculogenesis model
[132]
Cancer :miR-296 HGS Promotion of angiogenesis Human ECs (HBMVEC) [133]
Cancer :miR-93 Integrin-p8 Promotion of angiogenesis Glioma cell line
(U87) ? ECs (Ypen)
[134]
Cancer :miR-378 SuFu
Fus-1
Promotion of proliferation
and angiogenesis
Glioma cell line (U87) [135]
K-Ras, Myc
over-expressed
miR-17-92 TSP1 Promotion of angiogenesis Mouse colonocytes [138]
:miR-18 SMAD4 [139]
:miR-19 CTGF [138]
:miR-20 TGFbR2 [139]
TNF-a VEGF, bFGF :miR-126 VCAM1 Leukocyte adhesion Human ECs (HUVEC) [141]
PIK3R2 (p85) Promotion of angiogenesis Human ECs (HUVEC) [142, 143]
SPRED1 Promotion of angiogenesis Human ECs (HUVEC, HAEC) [142–144]
PAK1 Regulation of vascular
integrity
Human ECs (HUVEC) [145]
Cancer IRS1 Inhibition of proliferation
(G0/G1 arrest)
Human breast cancer (MCF7),
HEK293
[149]
VEGFA Inhibition of proliferation
(G0/G1 arrest)
Lung cancer cell lines [150]
Human breast cancer (MCF7) [151]
CRK Inhibition of adhesion,
invasion, proliferation
Lung cancer cell lines [152]
Gastric cancer cell line [153]
EGFL7 Inhibition of proliferation Lung cancer cell line [154]
a Target validated by gene reporter assay
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integrin subunits alfa5 (ITGA5) were inversely related to
miR-92 expression and ITGA5 was proposed as a direct
target of miR-92a [131].
Pro-angiogenic microRNAs
MiR-132 is a microRNA able to turn on the angiogenic
switch. Anand et al. [132] identified miR-132 in two
models of activated ECs, namely HUVEC treated with
either VEGF or bFGF, and in a human embryonic stem
cell vasculogenesis model. An up-regulation of miR-132
has been found in HUVEC treated with conditioned
media from breast and pancreatic tumor cell lines, in the
endothelium of human breast tumors, in hemangioma and
in the endothelium of murine pancreatic tumors. The
miR-132 expression is inversely correlated with the one
of its validated target, p120RasGAP (encoded by Rasa1
gene), a negative regulator of Ras. An anti-miR-132
treatment inhibited Matrigel plug angiogenesis, but it was
not effective in mice with an inducible deletion for
Rasa1. Importantly, the authors exploited an innovative
technology based on integrin amb3-targeted nanoparticles,
to selectively deliver anti-miR-132 into tumor endothe-
lium. The systemic administration of the nanoparticles
was able to increase p120RasGAP in tumor vasculature
and significantly decrease tumor burden and angiogenesis
of an orthotopic xenograft mouse model of human breast
carcinoma [132]. Another microRNA, miR-296 was
demonstrated to be up-regulated in HBMVEC (human
brain microvascular ECs) cocultured with a tumor cell
line (human U87 glioma cells) or treated with medium
from U87 cells or just with VEGF or bFGF and also in
tumor blood vessels from highly angiogenic glioma
specimens from human patients [133]. MiR-296 was
shown to prevent the degradation of the growth factor
receptors VEGFR2 and PDGFRb by decreasing HGS
(hepatocyte growth factor-regulated tyrosine kinase sub-
strate), which is involved in the regulation of the levels
of these receptors. Also in this case, as for miR-132,
miR-296 expression promoted angiogenesis, while its
inhibition by cholesterol-conjugated antagomir-296 anti-
sense oligonucleotide reduced tumor neovascularization
in mice.
Conversely, miR-93 seems to play a slightly different
role in the angiogenic switch. When it was over-expressed
in U87 it did not promote cell proliferation; nevertheless
U87-derived tumor over-expressing miR-93 were bigger
and displayed more blood vessels. MiR-93 seems to have a
role in promoting tumor cell survival through the inhibition
of integrin-b8. The overall mechanisms led to an increase
in angiogenesis and a better tumor nutrition supply. These
findings were further supported by U87-EC coculture
experiments [134].
Another microRNA that promotes tumor growth, cell
survival and angiogenesis is miR-378 [135]. It was found
over-expressed in several tumors and it promoted the for-
mation of larger vessels. It acts by targeting the tumor
suppressor SuFu and Fus-1.
In the human genome, the miR-17-92 cluster encodes
six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-
19b-1, and miR-92-1), which are tightly grouped within an
800-bp region of human chromosome 13. These microR-
NAs have been often found to play a role in cancer and
development [136] and in postnatal angiogenesis, where
their induction in Dicer-silenced mice promoted TSP1
down-regulation and consequent promotion of cell prolif-
eration and angiogenesis [137]. The cluster has been also
involved in augmentation of tumor angiogenesis in a model
of p53 null, K-Ras and Myc over-expressing colonocytes
engrafted into syngenic mice. The cluster over-expression,
which recapitulated Myc-induced phenotype (in the p53
null and Ras over-expressing context), did not promote cell
proliferation in vitro, nor in vivo, until the threshold tumor
size to promote the angiogenic switch was reached. The
microarray analysis did not reveal the induction of pro-
angiogenic factors, but antiangiogenic factors, like TSP1
and proteins with TSP1 repeats, as CTGF and clusterin
were in the list of Myc-downregulated genes. TSP1 and
CTGF have been validated as miR-17-92 targets (miR-18
is primarily responsible for TSP1 and miR-19 for CTGF
down-regulation) [138], while clusterin is indirectly regu-
lated by miR-17-92, which acts on clusterin-activating
TGFb signaling; specifically, miR-20a down-regulates
TGFb receptor type 2 and miR-18 down-regulates Smad 4
expression [139].
MiR-126 is among the most expressed microRNA in
ECs. It is encoded by an intron of Egfl7 gene and for that
miR-126 and Egfl7 are cotranscribed [140]. This microR-
NA was shown to regulate the TNF-a-stimulated
expression of VCAM1 (vascular cell adhesion molecule 1)
and therefore to mediate leukocyte adhesion. The trans-
fection of an antisense miR-126 promoted VCAM1
expression and leukocyte binding to HUVEC, whether the
over-expression of miR-126 decreased the protein expres-
sion and leukocytes adhesion [141]. MiR-126 was also
found to have a role in vascular integrity and angiogenesis.
Fish et al. [142] reported that HUVEC transfected (nucle-
oporated) with a morpholino antisense to miR-126 showed
reduced migration and reduced proliferation, due to an
increase in apoptosis, in response to VEGF and bFGF. The
knocking down of miR-126 in fertilized zebrafish eggs
produced no differences in morphology or vascular pat-
terning, but the zebrafish transgenic line Tg (gata1: dsRed),
which expresses dsRed in blood cells, revealed severe
cranial hemorrhages. The proposed mechanism of action is
that miR-126 controls the VEGF downstream pathways in
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two ways: by inhibiting PIK3R2 (p85b) expression [142,
143], which negatively regulates the activity of PI3 kinase,
and by inhibiting SPRED1 (Sprouty-related EVH1 domain-
containing protein 1) [142–144], which represses the acti-
vation on the MAP kinase. Moreover, p21-activated
kinase1 (pak1), whose over-expression causes cranial
hemorrhage, was shown to be a target of both miR-126a
(named miR-126 in previous literature) and miR-126b
(which differs from miR-126a by just one nucleotide in the
mature sequence) [145]. MiR-126-deficient mice were
created by homologous recombination (miR-126-/-) [144]
and by Cre-lox system, producing miR-126D/D mice [143].
These types of transgenic mice presented, respectively,
about 40 and 50% of embryonic lethality due to severe
systemic edema, multifocal hemorrhages and leaky vessels,
while the surviving neonates exhibited delayed postnatal
retinal angiogenesis. Surprisingly, these phenotypes were
previously reported for Egfl7 gene-trap and lacZ knock-in
mice [146], but Egfl7D/D mice, wherein miR-126 was not
eliminated, were phenotypically normal [143]. This sug-
gests that the altered phenotypes previously attributed to
Egfl7 were actually due to miR-126 deletion. MiR-126 is
also involved in vascular remodeling guided by blood flow
in the aortic arch ECs. MiR-126 expression was shown to
be promoted by the flow-induced transcription factor klf2,
therefore linking hemodynamic forces to VEGF signaling
[147].
Besides regulating angiogenesis and vascular integrity,
miR-126 was found under-expressed in several microRNA
cancer profiles, like breast and lung cancers (for a review
see [148]). These findings addressed studies on miR-126 as
a cell cycle regulator and revealed that miR-126 inhibits
proliferation of cancer cells by promoting an arrest of cells
at G0/G1. This seems to be reached in several ways. MiR-
126, once over-expressed, appears able to target IRS1
protein in MCF7 and HEK293 [149]; to inhibit VEGFA in
lung cancer cell lines [150] and breast cancer lines [151]; to
inhibit CRK in lung cancer cell lines [152] and in gastric
cancer [153]; to inhibit EGFL7 in lung cancer cell lines
[154] (Table 2). Nevertheless, other studies revealed a
malignant role for miR-126 in promoting tumor angio-
genesis. Donnem et al. [155] found negative prognosis for
non-small cell lung carcinoma tumors wherein miR-126
was over-expressed and saw a weak but significant corre-
lation between miR-126 and VEGF expressions. When
stratified, the prognostic impact was highly associated with
squamous cell carcinoma patients or those patients with
nodal metastasis (compared to adenocarcinoma and large-
cell carcinoma patients). Another study reported that miR-
126 is highly over-expressed in lung metastases, compared
with primary lung tumors [156]. This would suggest that
the principal pathways regulated by miR-126 would lead to
promotion of angiogenesis during development, and
possibly in metastatic malignant tumors, while the high
level of miR-126 in ECs would help to maintain a resting
state by controlling cell cycle. More studies are needed to
properly assign a role for miR-126 in different contexts.
Secretory microRNAs
There are new emerging concepts about a systemic sig-
naling based on microRNAs. The discovery of microRNAs
in biological fluids [157] is opening new frontiers on the
study of microRNAs. Zampetaki et al. [158] isolated
apoptotic bodies and microparticles from plasma of
patients with type 2 diabetes and control subjects. Once
having extracted and analyzed microRNA expression, they
found lower plasma levels of miR-20b, miR-21, miR-24,
miR-15a, miR-126, miR-191, miR-197, miR-223, miR-
320, and miR-486 in diabetic patients. In particular, miR-
126, which is highly expressed in ECs, was consistently
under-represented also in apoptotic bodies shed from ECs
treated with high glucose. Since apoptotic bodies and
microparticles can be transferred to other cell types, the
authors suggested that low miR-126 plasma levels may
reduce the delivery of miR-126 to monocytes and con-
tribute to endothelial dysfunction.
Human ECs in vitro and murine endothelium in vivo
were in turn demonstrated to internalize microvesicles
(exosomes) secreted by monocytes (THP-1 cell line) or
isolated from plasma of atherosclerosis patients. These
microvesicles contained high levels of an exogenous
microRNA, miR-150, which was able to trigger EC
migration by reducing endothelial c-MYB protein levels
[159].
Currently, microRNAs are no longer seen just as
endogenous regulators of gene expression, but also as
reliable biomarkers for pathologies and secreted factors
able to mediate cell-to-cell communication.
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